Cases & Investigations

State of California v. Schering-Plough Corporation

On December 17, 2009, Schering-Plough Corporation (now known as Merck & Co.) agreed to pay $21.3 million to settle qui tam allegations that it knowingly inflated the prices of its drugs, causing California’s Medicaid Program, Medi-Cal, to overpay millions of dollars in reimbursement. 

  • Settled
  • False Claims Act/Qui Tam/Whistleblower
  • Read More >

State of Florida v. Dey

The State of Florida recently settled a whistleblower case against three pharmaceutical manufacturers and their corporate affiliates. The case, which was originally filed by a whistleblower represented by Berger Montague’s Whistleblower/Qui Tam Group, involved allegations that Roxane Laboratories, Dey and Warrick Pharmaceuticals violated the Florida False Claims Act by reporting inflated prices for their drugs dispensed by pharmacies and other providers which were then reimbursed by the Florida Medicaid program (which provides prescription drug coverage for the poor and disabled).

  • Settled
  • False Claims Act/Qui Tam/Whistleblower
  • Read More >

U.S. ex rel. John Doe v. Recovery Home Care, Mark Conklin, and Glen Castillo

Home healthcare is a wide range of healthcare services that can be given in your home for an illness or injury. Under Medicare, the United States pays for certain home health services rendered to Medicare beneficiaries who meet specific coverage requirements.

  • Settled
  • False Claims Act/Qui Tam/Whistleblower
  • Read More >

United States et al. ex rel. Ronald J. Streck v. Allergan, Inc. et al.

In a ruling on July 3, 2012, Judge Robreno denied Defendants’ Motion to Dismiss in part, allowing Plaintiff’s case to proceed against four pharmaceutical manufacturer Defendants (AstraZeneca, Biogen Idec, Cephalon and Genzyme).

  • Settled
  • False Claims Act/Qui Tam/Whistleblower
  • Read More >

United States et al. ex rel. Silver v. Omnicare, Inc. et al.

Nursing homes typically select a single institutional pharmacy – for example, Defendant Omnicare – to provide prescription drugs to all of that nursing home’s residents, regardless of each patient’s type of insurance (e.g., Medicare Part A, Medicaid, private insurance, etc.).

  • Settled
  • False Claims Act/Qui Tam/Whistleblower
  • Read More >

United States ex rel. Gale v. Omnicare, Inc.

Mr. Gale’s whistleblower complaint alleged a kickback scheme called “swapping,” asserting that Omnicare paid nursing home owners kickbacks in the form of heavily-discounted prescription drugs for Medicare Part A inpatients.

  • Settled
  • False Claims Act/Qui Tam/Whistleblower
  • Read More >

United States ex rel. HMI v. Pinnacle Bank

The United States has joined a whistleblower lawsuit against Pinnacle Bank. The lawsuit was filed by a whistleblower represented by Shauna Itri and Dan Miller of Berger Montague, a nationally known full-spectrum civil litigation law firm with one of the largest and most successful whistleblower practices in the U.S.

  • Settled
  • False Claims Act/Qui Tam/Whistleblower
  • Read More >

United States ex rel. Ven-A-Care of the Florida Keys, Inc. v. Apothecon, Inc.

Berger Montague represented the whistleblower, Ven-A-Care of the Florida Keys, Inc., a small pharmacy from Key West, Florida. The case included allegations that Apothecon submitted false and inflated Average Wholesale Prices for a number of its oncology and generic drugs.

  • Settled
  • False Claims Act/Qui Tam/Whistleblower
  • Read More >

United States ex rel. Ven-A-Care of the Florida Keys, Inc. v. Bristol Myers Squibb Co.

Berger Montague represented the whistleblower, Ven-A-Care of the Florida Keys, Inc., a small pharmacy from Key West, Florida. The case included allegations that Bristol submitted false and inflated Average Wholesale Prices for a number of its oncology and generic drugs.

  • Settled
  • False Claims Act/Qui Tam/Whistleblower
  • Read More >

United States v. AstraZeneca Pharmaceuticals, LP

In October 2009, the United States, through the U.S. Attorney’s Office in New Hampshire, recovered $124 million from four drug companies — Mylan Pharmaceuticals Inc., AstraZeneca Pharmaceuticals LP, UDL Laboratories Inc. and Ortho McNeil Pharmaceutical Inc. – for underpaying Medicaid, the joint federal-state program which provides prescription drug coverage to the poor and disabled.

  • Settled
  • False Claims Act/Qui Tam/Whistleblower
  • Read More >
Go to page: 1 2

Request A Free Consultation

  • This field is for validation purposes and should be left unchanged.